MGMT gene promoter appeared not to benefit from intensifying the TMZ schedule regarding median PFS and overall survival, whereas data are promising for patients with methylated MGMT promoter.
CONFLICT OF INTEREST NOTIFICATION

INTRODUCTION
The current standard of care in the treatment of newly diagnosed glioblastoma is combined chemoradiotherapy with concomitant and adjuvant temozolomide (TMZ) according to the phase III trial jointly conducted by the European Organisation for
Research and Treatment of Cancer (EORTC) and the National Cancer Institute of Canada (NCIC) (1) . This trial also demonstrated that hypermethylation of the promoter region of the DNA repair gene O 6 -methylguanine-DNA methyltransferase (MGMT) which partially mediates chemoresistance against alkylating agents such as TMZ or the nitrosoureas (2) correlates with improved survival in patients treated with combined radiotherapy and TMZ (3) . TMZ dosing schedules allowing a more prolonged exposure may result in higher cumulative doses (4-6) than the standard 5-day regimen (7) and may deplete MGMT in the tumor, thus sensitizing tumor cells to the toxic effects of TMZ. However, depletion of MGMT by prolonged exposure to TMZ not only affects tumor cells but also normal cells, particularly hematopoietic precursor cells, potentially enhancing hematologic toxicity (5) . Other dose-dense TMZ regimens did not show an unusual incidence of toxicities and also demonstrated promising efficacy data at recurrence (6) .
Preclinical and clinical studies suggest anti-tumoral effects of cyclooxygenase (COX)-2 inhibitors (8, 9) . COX-2 inhibition may result in a tumor cell-specific sensitization towards radiotherapy (10) and reduction of tumor neovascularization (11) . Expression of COX-2 correlates with shorter survival times in patients with glioma (12) . Though selective inhibition of COX-2 is regarded superior to nonselective COX inhibition, e.g. mediated by non-steroidal anti-inflammatory drugs (NSAID)s, in tumor therapy due to lacking adverse effects on gastrointestinal and platelet function, two available COX-2-selective inhibitors, rofecoxib and celecoxib, Weiler et al. 4 were in discussion for lethal cardiovascular complications before this trial was initiated.
The University of Tübingen Medical Center (UKT)-05 phase II trial exploited the antiangiogenic and radiosensitizing effects of the NSAID indomethacin (INDO) administered as a continuous maintenance therapy and the cytotoxic effects of an intensified concomitant and adjuvant (one week on/one week off) TMZ regimen in addition to radiotherapy in the first-line treatment of glioblastoma. Second-line therapy was at the discretion of the treating physician.
PATIENTS AND METHODS
Patients
Toxicity monitoring was performed monthly according to the Common Terminology
Criteria for Adverse Events (CTCAE; version 3.0). Hematologic toxicity was evaluated by weekly hemograms and monthly differential hemograms. Patients were to undergo contrast-enhanced MRI within 72 h after neurosurgery, four weeks after completion of radiotherapy, and every three months thereafter. Tumor progression was defined according to Macdonald criteria (14) .
End points and statistical analysis
The primary end point was median progression-free survival (PFS). Secondary end points were PFS rate at six months (PFS-6), overall survival (OS), OS rate at two years, and tumor remission rates. Assessment on an intention-to-treat basis required initiation of trial treatment. Survival data were calculated according to the KaplanMeier method (15) 
MGMT analysis
A tumor cell content of at least 80% was histologically determined. From each sample and the reference samples 200 to 500 ng of genomic DNA were treated with sodium bisulfite using the Qiagen EpiTect kit (Qiagen, Hilden, Germany) with the provided FFPE tissue protocol. The primer sequences used to detect methylated MGMT promoter sequences were 5′-tttcgacgttcgtaggttttcgc-3′ and 5′-gcactcttccgaaaacgaaacg-3′. This primer combination amplifies an 81-base pair (bp) fragment from methylated DNA. The primer sequences used to detect unmethylated MGMT promoter sequences were 5′-aactccacactcttccaaaaacaaaaca-3′ and 5′-tttgtgttttgatgtttgtaggtttttgt-3′. This primer combination amplifies a 93-bp fragment from unmethylated DNA (17) . The PCR products were separated on 2.5% agarose gels.
As a positive control for methylation, we used genomic DNA from the glioma cell line U87 with known MGMT hypermethylation. CpGenome universal unmethylated DNA Vial A (Chemicon International, Temecula, CA) served as a negative control for methylation. In addition, a control reaction without any template DNA was performed for both PCR experiments.
Weiler et al.
RESULTS
Patient characteristics
Of 49 patients with newly diagnosed glioblastoma screened, seven patients were enrolled into a competing phase I/IIa trial of cilengitide, TMZ and radiotherapy (18) and one patient was excluded from the trial assessment retrospectively because he died from a Legionellae pneumonia before the trial therapy was started. Along with the remaining 41 patients (Table 2) , one more patient than originally planned was accrued because at the end of the accrual period, two eligible patients consented at the same time.
Treatment
At the cutoff date (March 1, 2008) , the median follow-up interval for PFS was 18. 
DISCUSSION
First-line therapy with intensified TMZ combined with maintained daily INDO and involved-field radiotherapy plus concomitant daily low-dose TMZ was shown to be feasible and effective in patients with glioblastoma. In line with previous studies following other approaches (3, 18, 19) , MGMT gene promoter methylation was highly predictive for survival in glioblastoma patients receiving alkylating chemotherapy.
The PFS-6 of 70.7% in UKT-05 compares well with the results of the combined RT/TMZ treatment arm in the phase III randomized EORTC/NCIC trial that currently sets the benchmark for first-line therapy of glioblastoma (PFS-6: 53.9%) (1).
However, the median PFS of 7.6 months obtained in the UKT-05 trial is not relevantly superior to the historical control data of 6.9 months. To exclude the possibility that data were biased in the UKT-05 patient sample by selection for favorable prognostic factors, we compared the baseline patient characteristics in UKT-05 with the EORTC/NCIC trial (1, 20) . This comparison revealed no significant imbalance between the two trials.
As unlimited dose escalations of adjuvant TMZ were allowed in the UKT-05 trial protocol, the grade 4 lymphotoxicity rate per cycle was higher (10.3%) than observed in the recurrent glioma trial conducted at the same institutions (0.7%) (6) . Notably, grade 3/4 lymphopenia per patient did not exceed markedly grade 3/4 lymphopenia reported with a phase II trial that investigated the combined concomitant and adjuvant therapy with the integrin inhibitor cilengitide and six courses of conventionally-dosed TMZ in addition to radiotherapy in patients with newly diagnosed glioblastoma (55.8%) (18) . Moreover, the incidence of grade 3 through 5 opportunistic infections in the UKT-05 trial (4.9%) is the lowest for all reported trials that tested intensified TMZ dosing schedules.
Weiler et al. 14 The most important observation of the UKT-05 trial comes from the MGMT methylation efficacy data: In the subgroup of patients suffering from an MGMTinactive glioblastoma, there was a clinically relevant trend for a superior PFS. Yet, this trial did not indicate that this trend transformed into an overall survival benefit.
Compared to data from the EORTC/NCIC trial (3), patients with an unmethylated MGMT gene promoter appeared not to benefit from intensifying the TMZ schedule.
This profoundly affects the concept of enhanced MGMT depletion, as current efforts strive for an efficient reduction of MGMT activity in the tumor tissue to overcome chemoresistance by applying intensified TMZ dosing regimens. Several studies using TMZ at a three weeks on/one week off (21 of 28 days) schedule at recurrence in malignant glioma (21, 22) or at a one week on/one week off schedule in nonresectable glioblastoma (23) have investigated alternative dosing schedules for TMZ.
Encouraging data on the beneficial effects of a first-line treatment with doseintensified one week on/one week off TMZ were first obtained in the experimental arm of a randomized phase II trial (median PFS: 10.8 months; PFS-6: 67.1%; one year survival rate: 56.1%). However, that trial did not provide differential survival data regarding the methylation status of the MGMT gene promoter (24) . Preliminary evidence indicates that the one week on/one week off TMZ schedule could also be active in patients with tumors lacking MGMT gene promoter methylation (6) . The PFS-6 of 65.2% suggests that, in the first-line treatment situation, patients with MGMT-expressing tumors might benefit from the intensified TMZ schedule. In contrast, this translates not into a relevant overall improvement regarding median PFS and OS, similar to other trials for patients with MGMT-active glioblastoma (1, 3, 18, 19) . Conversely, the comparative statistical analysis with the current standard therapy documented a possible effect on PFS but failed to show an effect on OS in Weiler et al. 15 patients with a methylated MGMT gene promoter ( Table 4) 
